These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1102 related items for PubMed ID: 2106041

  • 21. A trial of bacillus Calmette-Guérin versus adriamycin in superficial bladder cancer: a South-West Oncology Group Study.
    Mori K, Lamm DL, Crawford ED.
    Urol Int; 1986; 41(4):254-9. PubMed ID: 3538593
    [Abstract] [Full Text] [Related]

  • 22. Optimal BCG treatment of superficial bladder cancer as defined by American trials.
    Lamm DL.
    Eur Urol; 1992; 21 Suppl 2():12-6. PubMed ID: 1396941
    [Abstract] [Full Text] [Related]

  • 23. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
    Yutkin V, Pode D, Pikarsky E, Mandelboim O.
    J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
    [Abstract] [Full Text] [Related]

  • 24. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
    Haaff EO, Dresner SM, Ratliff TL, Catalona WJ.
    J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
    [Abstract] [Full Text] [Related]

  • 25. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
    Kelley DR, Ratliff TL, Catalona WJ, Shapiro A, Lage JM, Bauer WC, Haaff EO, Dresner SM.
    J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
    [Abstract] [Full Text] [Related]

  • 26. 15-year experience on intravesical therapy of T1G3 urinary bladder cancer: a conservative approach.
    Cheng CW, Chan SF, Chan LW, Chan CK, Ng CF, Cheung HY, Chan SY, Wong WS, Lai FM, Li ML.
    Jpn J Clin Oncol; 2004 Apr; 34(4):202-5. PubMed ID: 15121756
    [Abstract] [Full Text] [Related]

  • 27. Intravesical chemotherapy versus immunotherapy for superficial bladder cancer.
    Huben RP.
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):17-22. PubMed ID: 8727806
    [Abstract] [Full Text] [Related]

  • 28. Bladder cancer immunotherapy.
    Lamm DL, Thor DE, Stogdill VD, Radwin HM.
    J Urol; 1982 Nov; 128(5):931-5. PubMed ID: 6757467
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R, Metcalfe MJ, Tabayoyong WB, Guo CC, Nogueras González GM, Navai N, Grossman HB, Dinney CP, Kamat AM.
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [Abstract] [Full Text] [Related]

  • 34. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW, Chan SF, Chan LW, Chan CK, Ng CF, Cheung HY, Chan SY, Wong WS, Lai FM, To KF, Li ML.
    Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
    [Abstract] [Full Text] [Related]

  • 35. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
    Brake M, Loertzer H, Horsch R, Keller H.
    J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D, Situm M, Eterovic D, Dogas Z, Gotovac J.
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [Abstract] [Full Text] [Related]

  • 38. [Intravesical instillation of bacillus Calmette-Guerin for superficial bladder carcinoma: study on significance of additional maintenance instillations of bacillus Calmette-Guerin].
    Yabusaki N, Komatsu H, Tago K, Yamada Y, Ueno A.
    Nihon Hinyokika Gakkai Zasshi; 1991 Feb; 82(2):290-6. PubMed ID: 1904120
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study.
    Pfister C, Kerkeni W, Rigaud J, Le Gal S, Saint F, Colombel M, Guy L, Wallerand H, Irani J, Soulie M, Cancer Committee of French Urological Association.
    Int J Urol; 2015 Jan; 22(1):53-60. PubMed ID: 25256813
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 56.